Xiangwan Miao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiangwan Miao has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Atala
Wake Forest Institute for Regenerative Medicine, Wake Forest University Health Sciences, North Carolina, USA
1 shared publication - Bin Ye
Department of Otolaryngology and Head and Neck Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication Chenyu Zhang
Department of Orthopedic Surgery, Shanghai Key Laboratory of Orthopedic Implants, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publicationCui Fan
Department of Otolaryngology & Head and Neck Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of, Medicine, Shanghai, China
1 shared publicationHaixia Hu
Department of Otolaryngology & Head and Neck Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of, Medicine, Shanghai, China
1 shared publicationHao Wang
Department of Otorhinolaryngology, Ruijin Hospital Lu Wan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 1 May 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 59, 579-594
Construction of biomimetic gradient-structured cartilage organoids and mechanistic study of their application for cartilage rejuvenation
Articular cartilage damage, an important cause of osteoarthritis (OA), is often caused by a senescent cartilage microenvironment and insufficient repair of chondrocytes. These effects are due to limited availability and a depleted stemness phenotype of chondrocyte stem cells, leading to the failure of cartilage repair and exacerbation of symptoms. In this study, a biomimetic gradient-structured cartilage organoid (BGSC-organoid) culture system was developed using decellularized cartilage extracellular matrix infused with extracellular vesicles from SOX9-overexpressing bone marrow-derived stem cells (SBEVs) to induce the rejuvenation of senescent chondrocytes. Single-cell sequencing revealed that a subpopulation of chondrocytes could be rejuvenated in the BGSC-organoid culture system. Moreover, an ex vivo osteoarthritis-on-a-chip (OAOC) model with cyclic mechanical stimulation was constructed to simulate the mechanical microenvironment of cartilage. BGSC-organoids exhibited sustained release of chondrocyte-protective factors and good mechanical resistance through the Vimentin/14-3-3/FOXO3 pathway. Animal studies showed that BGSC-organoids preserved a hyaline-like cartilage phenotype in vivo and delayed the degeneration of articular cartilage and intervertebral discs. Efficient expansion of human cartilage organoids with enhanced regenerative capabilities represents a promising approach for joint regeneration.
- 1 May 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 59, 579-594
Open AccessConstruction of biomimetic gradient-structured cartilage organoids and mechanistic study of their application for cartilage rejuvenation
Articular cartilage damage, an important cause of osteoarthritis (OA), is often caused by a senescent cartilage microenvironment and insufficient repair of chondrocytes. These effects are due to limited availability and a depleted stemness phenotype of chondrocyte stem cells, leading to the failure of cartilage repair and exacerbation of symptoms. In this study, a biomimetic gradient-structured cartilage organoid (BGSC-organoid) culture system was developed using decellularized cartilage extracellular matrix infused with extracellular vesicles from SOX9-overexpressing bone marrow-derived stem cells (SBEVs) to induce the rejuvenation of senescent chondrocytes. Single-cell sequencing revealed that a subpopulation of chondrocytes could be rejuvenated in the BGSC-organoid culture system. Moreover, an ex vivo osteoarthritis-on-a-chip (OAOC) model with cyclic mechanical stimulation was constructed to simulate the mechanical microenvironment of cartilage. BGSC-organoids exhibited sustained release of chondrocyte-protective factors and good mechanical resistance through the Vimentin/14-3-3/FOXO3 pathway. Animal studies showed that BGSC-organoids preserved a hyaline-like cartilage phenotype in vivo and delayed the degeneration of articular cartilage and intervertebral discs. Efficient expansion of human cartilage organoids with enhanced regenerative capabilities represents a promising approach for joint regeneration.
- 21 January 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (6) , 1475-1487
SREBP1-mediated lipid metabolism reprogramming drives malignant progression and therapeutic resistance in HPSCC organoids and animal models
Head and neck squamous cell carcinoma (HNSCC) presents significant therapeutic challenges owing to its elevated recurrence rate and resistance to chemotherapeutic interventions. Tumor organoid models serve as essential platforms for investigating tumor physiology and pathological functions in vivo for its similarities in recapitulating the spatial structure of HNSCC. We employed HPSCC organoids from typical cell line and patient tissues, which faithfully recapitulated the tumor architecture, combined with CRISPR/Cas9 screening and TCGA-HNSCC database analysis. We identified SREBP1, a master regulator of lipid metabolism, as a key molecule whose expression escalates during HNSCC progression and correlates with improved patient survival and chemotherapy response. Functional studies demonstrated that SREBP1 downregulation conferred resistance to cisplatin and reduced cell death in both organoid and xenograft models in human hypopharyngeal carcinoma (HPSCC). We also found that the downregulation of SREBP1 was associated with enhanced resistance to cisplatin and a reduction in cell death in HPSCC-organoid models ex vivo and xenograft mouse models in vivo. Our findings establish SREBP1-mediated lipid rewiring as a critical determinant of HNSCC pathogenesis and treatment outcomes. Consequently, our model offers a promising solution for the swift and accurate evaluation of chemotherapy efficacy and identifies SREBP1 as a potential therapeutic target in HPSCC.
- 21 January 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (6) , 1475-1487
SREBP1-mediated lipid metabolism reprogramming drives malignant progression and therapeutic resistance in HPSCC organoids and animal models
Head and neck squamous cell carcinoma (HNSCC) presents significant therapeutic challenges owing to its elevated recurrence rate and resistance to chemotherapeutic interventions. Tumor organoid models serve as essential platforms for investigating tumor physiology and pathological functions in vivo for its similarities in recapitulating the spatial structure of HNSCC. We employed HPSCC organoids from typical cell line and patient tissues, which faithfully recapitulated the tumor architecture, combined with CRISPR/Cas9 screening and TCGA-HNSCC database analysis. We identified SREBP1, a master regulator of lipid metabolism, as a key molecule whose expression escalates during HNSCC progression and correlates with improved patient survival and chemotherapy response. Functional studies demonstrated that SREBP1 downregulation conferred resistance to cisplatin and reduced cell death in both organoid and xenograft models in human hypopharyngeal carcinoma (HPSCC). We also found that the downregulation of SREBP1 was associated with enhanced resistance to cisplatin and a reduction in cell death in HPSCC-organoid models ex vivo and xenograft mouse models in vivo. Our findings establish SREBP1-mediated lipid rewiring as a critical determinant of HNSCC pathogenesis and treatment outcomes. Consequently, our model offers a promising solution for the swift and accurate evaluation of chemotherapy efficacy and identifies SREBP1 as a potential therapeutic target in HPSCC.